Work

A phase II study of perioperative mFOLFOX plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ) and stomach.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.4047

Authors: Weijing Sun, Anwaar Saeed, Raed Moh'd Taiseer Al-Rajabi, Anup Kasi, Nirmal K Veeramachaneni, Mazin Francis Al-Kasspooles, Joaquina Celebre Baranda, Milind A. Phadnis, Andrew K. Godwin, Mojtaba Olyaee, Rashna Madan, Natalie Streeter, Alykhan Nagji, Stephen K. Williamson

Institutions: University of Kansas Medical Center, The University of Kansas Cancer Center, The University of Texas at San Antonio Health Science Center, University of Kansas

Language: English

Topic: Esophageal Cancer Research and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286295207

Cites:

Cited by: 6

Related to: 10